1-3 of 3
Andrew J. Pierce
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition

Haihong Zhong, Cui Chen, Ravinder Tammali, Shannon Breen, Jing Zhang, Christine Fazenbaker, Maureen Kennedy, James Conway, Brandon W. Higgs, Nicholas Holoweckyj, Rajiv Raja, Jay Harper, Andrew J. Pierce, Ronald Herbst, David A. Tice
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2019) 18 (1): 89–99.
https://doi.org/10.1158/1535-7163.MCT-18-0314
Published: 02 January 2019
View article titled, Improved Therapeutic Window in <em>BRCA</em>-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition
Open the PDF for Improved Therapeutic Window in <em>BRCA</em>-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition in another window
Includes: Supplementary data
Journal Articles

Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein

Michael D. Oberst, Catherine Augé, Chad Morris, Stacy Kentner, Kathy Mulgrew, Kelly McGlinchey, James Hair, Shino Hanabuchi, Qun Du, Melissa Damschroder, Hui Feng, Steven Eck, Nicholas Buss, Lolke de Haan, Andrew J. Pierce, Haesun Park, Andrew Sylwester, Michael K. Axthelm, Louis Picker, Nicholas P. Morris, Andrew Weinberg, Scott A. Hammond
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (5): 1024–1038.
https://doi.org/10.1158/1535-7163.MCT-17-0200
Published: 30 April 2018
View article titled, Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Open the PDF for Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein in another window
Includes: Supplementary data
Journal Articles

A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non–EGFR-Mediated Pathways

Jonathan Rios-Doria, Darrin Sabol, Jon Chesebrough, Dave Stewart, Linda Xu, Ravinder Tammali, Li Cheng, Qun Du, Kevin Schifferli, Ray Rothstein, Ching Ching Leow, Jenny Heidbrink-Thompson, Xiaofang Jin, Changshou Gao, Jay Friedman, Brandy Wilkinson, Melissa Damschroder, Andrew J. Pierce, Robert E. Hollingsworth, David A. Tice, Emil F. Michelotti
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2015) 14 (7): 1637–1649.
https://doi.org/10.1158/1535-7163.MCT-14-1040
Published: 06 July 2015
View article titled, A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non–EGFR-Mediated Pathways
Open the PDF for A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non–EGFR-Mediated Pathways in another window
Includes: Supplementary data